 "Aurobindo Pharma receives US FDA's nod for tranexamic acid and paricalcitol")
Aurobindo Pharma on January 16, 2016 announced that it has received final approval from the US Food & Drug Administration (USFDA) for manufacturing tranexamic acid injection (100 mg/mL) and paricalcitol capsules (1 mcg, 2 mcg, and 4 mcg).
Tranexamic acid injection is used in the treatment of short-term control of bleeding in hemophiliacs, including dental extraction procedures. Aurobindo Pharma expects to launch tranexamic acid injection, a generic version of Pharmacia and Upjohn Company’s Cyklokapron, by the end of Q4 FY15-16. This product is in the WHOs list of essential medicines. Tranexamic acid injection has an estimated market size of $ 50 million for the twelve months ending November 2015, according to IMS.
Paricalcitol capsule, a generic version of Abbvie’s Zemplar, is used for the prevention and treatment of high levels of parathyroid hormone in certain patients with chronic kidney disease. The approved product has an estimated market size of $ 38 million for the twelve months ending November 2015, according to IMS. Aurobindo Pharma will launch paricalcitol capsule in Q1 FY16-17.
Tranexamic acid injection is used in the treatment of short-term control of bleeding in hemophiliacs, including dental extraction procedures. Aurobindo Pharma expects to launch tranexamic acid injection, a generic version of Pharmacia and Upjohn Company’s Cyklokapron, by the end of Q4 FY15-16. This product is in the WHOs list of essential medicines. Tranexamic acid injection has an estimated market size of $ 50 million for the twelve months ending November 2015, according to IMS.
Paricalcitol capsule, a generic version of Abbvie’s Zemplar, is used for the prevention and treatment of high levels of parathyroid hormone in certain patients with chronic kidney disease. The approved product has an estimated market size of $ 38 million for the twelve months ending November 2015, according to IMS. Aurobindo Pharma will launch paricalcitol capsule in Q1 FY16-17.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%